Objective: To observe the clinical efficacy of Jiangtang Tongmai capsules in treating macroangiopathy of type 2 diabetes mellitus

and to investigate its influence on inflammatory response and microcirculation. Method: One hundred and forty-four patients were randomly divided into the control group (71 cases) and the observation group (73 cases) by a random number table. Patients in the control group received conventional glucose and blood pressure control

and took 40 mg simvastatin tablets and 100 mg aspirin enteric-coated tablets once daily. On the basis of the control group

patients in the observation group added 3 Jiangtang Tongmai capsules thrice daily. All patients in both two groups received 4 months of treatment. Before and after treatment

the carotid intermedium thickness and size of plaque were detected by color Doppler ultrasound. Levels of fasting blood-glucose(FBG)

2-hour postprandial blood glucose (PBG)

glycated serum protein (GSP)

tumor necrosis factor-α (TNF-α)

high-sensitivity C-reactive protein (hs-CRP)

interleukin-6 (IL-6)

adiponectin (APN)

fibrinogen (FIB)

platelet maximum aggregation rate (MPAR) and D-dimer(D-D) were detected. Result: After treatment

cases of thicken of carotid intermedium thickness and size of plaque in the observation group were lower

carotid intermedium thickness and size of plaque were smaller than those in the control group (P<0.01). Level of GSP in the observation group was lower than that in the control group (P<0.01)

and there was no statistically significant difference for the levels of FBG and PBG between two groups. Levels of TNF-α

hs-CRP

IL-6 D-D

FIB and MPAR in the observation group were lower (P<0.01)

and level of APN was higher than those in the control group (P<0.01). Conclusion: Jiangtang Tongmai capsules could reduce the incidence rate of macroangiopathy of type 2 diabetes mellitus

and its mechanism of action may be related to reducing the symptoms of low rank inflammatory reaction and ameliorating microcirculation.